The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams
Phase: NA
Conditions: Uterine Cervical Dysplasia, Uterine Cervix Cancer
Sponsor: University of British Columbia

SAFE #H16-03194 v.3 2017-05-29 
 
1 of 12
The SAFE Study: Satisfaction and Adherence to Follow-Up with Colposcopy 
Exams 
 
 
 
 
Principal Applicant 
Dr. Marette Lee, MD, MPH, FRCSC 
Gynecologic Oncology, Vancouver General Hospital & British Columbia Cancer Agency 
Program Director, BC Provincial Colposcopy Program 
 Marette.Lee@vch.ca 
604-875-4268 
 
Co-applicants 
 
Dr. Lori Brotto, PhD, R Psych 
 
Executive Director, Women’s Health Research Institute 
Canada Research Chair in Women’s Sexual Health 
University of British Columbia 
Lori.Brotto@vch.ca 
604-875-4111 ext. 68898 
 
Dr. Sarah Mah, MD 
University of British Columbia 
PGY-2 Obstetrics and Gynecology 
Sarah.Mah@alumni.ubc.ca 
778-580-5106 
 
Maggie Bryce 
Research Assistant, University of British Clumbia 
Maggie.Bryce@vch.ca 
604-716-4111 
 
Susan Jane Keast 
Nurse and Research Coordinator, Obstetrics and Gynecology 
University of British Columbia 
Susan.Keast@vch.ca 

SAFE #H16-03194 v.3 2017-05-29 
2 of 12
TITLE  
The SAFE Study: Satisfaction and Adherence to Follow-Up with Colposcopy Exams 
 
LAY SUMMARY 
This study is intended to improve communication of colposcopy results and follow-up 
recommendations to patients. Current practice involves results being forwarded from the 
colposcopy clinic to the family/referring physician who then informs the patient. We are testing 
an intervention informed by focus groups in which a trained colposcopy nurse (patient liaison) 
contacts patients directly with their results and follow-up recommendations while providing 
education and support. We will examine whether this intervention improves patient satisfaction, 
reduces anxiety, and improves rates of adherence to follow-up and treatment appointments 
compared to the current practice.  
 
SUMMARY 
Cervical cancer is largely preventable with regular Pap smear screening that detects pre-
cancerous changes that can be diagnosed and treated with colposcopy. This process is limited by 
patient adherence to the follow-up and treatment recommendations. Currently at Vancouver 
General Hospital (VGH), the largest colposcopy clinic in the province, results are forwarded 
from the colposcopy clinic to the family/referring physician who informs patients of results and 
recommendations. Inefficiencies, omissions or errors in this step may cause patient 
dissatisfaction, missed appointments, increased costs, and compromise patient outcomes. The 
primary objective of this study is to examine whether having a trained colposcopy nurse contact 
patients directly with their results and follow-up recommendations while providing education 
and support will improve patient satisfaction and reduce anxiety. The secondary aims are to 
compare the timeliness of receipt of results, rates of adherence to follow-up and treatment 
appointments, and potentially long-term clinical outcomes between the control and intervention 
groups.  
 
The first phase of the study involves patient focus groups that will be interviewed about their 
experiences in colposcopy and what elements of a patient liaison interaction would be most 
important to them (REB#H16-01422). This information will inform the development of the 
patient liaison role and approaches to patient interaction to be utilized in the intervention in the 
second phase (current proposal). The second phase will entail a randomized controlled trial 
comparing patient anxiety, satisfaction and adherence to follow-up between a control group 
(current practice) versus the intervention group exposed to the patient liaison at the VGH 
Colposcopy Clinic. For the primary aim, a questionnaire containing items pertaining to patient 
anxiety and satisfaction with their experience of receiving their colposcopy results will be 
administered both to the intervention and control groups and the mean scores pertaining to 
anxiety and satisfaction will be compared using two-tailed t-tests. For the secondary aim, a chart 
review at 6-12 months following the initial colposcopy visit will examine the rates of compliance 
with the recommended follow-up or treatment visits and histologic diagnoses, and comparisons 
will be sought between the intervention and control groups using z-score test. 
 

SAFE #H16-03194 v.3 2017-05-29 
3 of 12
BACKGROUND AND SIGNIFICANCE 
Cervical cancer is the second most common cancer in women worldwide (incidence of 529,800 
new cases annually), and the third leading cause of cancer death1,2. Given the natural history of 
cervical cancer, cytologic screening (Pap smears) for precursor neoplastic lesions with referral to 
colposcopy has significantly reduced the morbidity and mortality associated with invasive 
cervical carcinoma in jurisdictions with screening programs. However, the effectiveness of 
screening programs for this largely preventable cancer is limited by default rates from 
colposcopy, which range from 3-9% for initial appointments and 6-16% for subsequent treatment 
or follow-up visits1,7. A randomized trial found that 20% of women after a biopsy confirmed 
diagnosis of CIN (cervical intraepithelial neoplasia) did not attend their recommended treatment 
appointment5. Follow-up rates following initial treatment were also found to be poor in one 
prospective study in which only 31% of women attended the recommended follow-up 
colposcopy appointment and only 60% had follow-up at 17 months14. Delayed and missed 
appointments not only expose women to the risk of increased morbidity or disease progression, 
but they also reduce the efficiency of the colposcopy system for the wider population, thereby 
increasing costs1. 
 
A critical step in the colposcopy pathway is communicating results and recommendations for 
further treatment or follow-up to patients. Communication delays, breakdowns in communication 
between specialists and primary care providers, and a lack of understanding by patients regarding 
the significance of their results and necessity for further intervention or follow-up have all been 
identified as potential contributors to default from colposcopy1,6,8.  Ethnic minorities and those of 
low socioeconomic status are known to have lower rates of cancer screening associated with late-
stage presentations and increased mortality. These patients are particularly vulnerable to 
breakdowns in the communication of results and follow-up plans, compounded by cultural and 
language barriers5,13. A recent qualitative focus group study found that patients value receiving 
results in a timely fashion from a clinically trained staff member with an understanding of the 
impact of the test result8. Correspondingly, studies have shown that adherence to screening, 
treatment and follow-up have improved with telephone-based interventions in which trained 
patient navigators contact patients with appointment reminders, education regarding the rationale 
for each test, follow-up for abnormal test results and counseling for barriers to attendance5,6. 
These interventions have also been found to be effective in ethnic or socioeconomic populations 
at higher risk for non-adherence13. Anxiety has been identified as a strong correlate of the 
colposcopy process, and is found to be elevated before, during, and after clinic procedures and 
may negatively impact adherence to recommendations6,12. There is evidence that providing 
patients simple (rather than complex) information significantly decreases their anxiety associated 
with colposcopy4,9,11. 
 
In our setting, the Vancouver General Hospital (VGH) Colposcopy Clinic is the largest of its 
kind in British Columbia, comprised of seven clinics per week attended by ten physician 
specialists who see 15-20 patients per clinic for diagnostic and treatment services. Following a 
clinic visit, a colposcopy report with results and recommendations is issued to the patient’s 
family/referring physician, typically within 2-3 weeks. It is the responsibility of the individual 
patient to follow-up with their provider for the results, or for the family physician/referring 
provider to initiate contact with the patient. The lack of direct contact between the colposcopy 
clinic and patients regarding test results or ongoing follow-up limits patient engagement and 

SAFE #H16-03194 v.3 2017-05-29 
4 of 12
increases opportunities for communication breakdown. This has the potential to compromise 
patient outcomes and patient satisfaction and contributes to inefficiencies in the healthcare 
system. 
 
In the proposed second phase of this study, we aim to utilize information gathered from phase 1 
to inform an intervention where a patient liaison nurse will serve as the link between new 
patients and the colposcopy clinic by communicating results along with treatment or follow-up 
recommendations to patients. She would explain the rationale behind recommendations and be 
available to answer patient questions. If this intervention is demonstrated to improve patient 
anxiety and satisfaction associated with colposcopy and adherence to follow-up and treatment, 
these results would then support larger studies and provide evidence to advocate for resources to 
offer this service to all colposcopy patients at VGH and beyond. 
 
HYPOTHESIS AND OUTCOMES 
1. Primary outcome: We hypothesize that the intervention group will have lower mean state 
anxiety scores as measured by the State Trait Anxiety Inventory (STAI). 
2. Primary outcome: We hypothesize that participants in the intervention arm will demonstrate 
higher:  
● A) Overall satisfaction with their colposcopy experience and interactions with 
colposcopy healthcare professionals; we anticipate higher patient satisfaction scores as 
well as positive qualitative themes from open-ended questions in the intervention group 
(PSQ-18 and VSQ-9 Inventories) 
● B) Satisfaction with the information and education they receive regarding colposcopy, 
their diagnoses and follow-up recommendations; we anticipate higher scores on 
questionnaire items that measure these factors in the intervention group (PSQ-18 and 
VSQ-9 Inventories) 
3. Secondary outcome: We hypothesize that patients in the intervention group will receive results 
sooner. 
4.  Secondary outcome: We hypothesize that participants in the intervention arm will 
demonstrate greater:  
● A) Knowledge of their colposcopy diagnosis; we anticipate a higher rate of accuracy 
between the participant self-reported colposcopy diagnosis and actual diagnosis 
● B) Adherence to treatment and follow-up recommendations; we anticipate higher rates 
of follow-up/treatment visit attendance in the intervention group   
 
STUDY DESIGN AND METHODOLOGY 
This is phase two of a two-part study. The first phase employs qualitative methodology with 
focus groups. Themes from these focus groups will inform development of the nurse-led patient 
liaison intervention to be employed in the second phase. The first phase has been reviewed in a 
separate Ethics application (REB#H16-01422). 
 
This is a randomized controlled trial to compare patients who participate in the patient liaison 
intervention (intervention group) to those who continue with the current system of results 
reporting via the family/referring physician (control group). Following recruitment and consent, 
patients will be randomized to the intervention or control group. The control group will receive 
the standard of care for colposcopy results reporting via their referring physician. Following their 

SAFE #H16-03194 v.3 2017-05-29 
5 of 12
colposcopy visit, control patients are given a slip of paper reminding them to call their 
family/referring physician for their colposcopy results in three weeks if they have not yet been 
contacted. Upon receipt of the final pathology, colposcopy reports are prepared by the 
colposcopists and forwarded to family/referring physicians typically within 2-3 weeks of the 
visit. Patients then receive the results of their colposcopy report from their family/referring 
physician by whatever method of communication preferred by that provider. 
 
The participants randomized to the intervention group will be exposed to the patient liaison in 
receiving their colposcopy report results and recommendations. Rather than receive results from 
their referring/family physician, an experienced colposcopy nurse will contact participants once 
the colposcopists complete the final colposcopy report. The colposcopy report will inform the 
referring provider that these patients will be informed of the results. The colposcopy nurse will 
provide an explanation of the colposcopy results and subsequent follow-up or treatment 
recommendations, be available to answer patient questions (within her scope), offer educational 
or support resources to patients. She will forward any patient questions beyond her scope to the 
patient’s colposcopist who may then provide answers to the patient liaison or to the patient 
directly depending on the complexity and nature of the question.  
 
The research coordinator (M. Bryce) will subsequently contact all participants (control and 
intervention groups) to complete a questionnaire following the communication of their 
colposcopy report. All participants following consent will be asked to provide their preferred 
contact method (email, telephone) and whether they prefer to access the questionnaire via an 
Internet link sent to their email or to complete it verbally via telephone with the research 
coordinator. Control participants will be contacted within 3-4 weeks of their initial colposcopy 
visit to permit time for communication of their results from their family/referring physician. 
Intervention group participants will be contacted once the patient liaison nurse has informed the 
research coordinator that the results have been communicated to the participant. Reminders to 
complete the questionnaire will be sent at weekly intervals—twice via email, and a third time via 
telephone. Patients who fail to complete the questionnaire after three reminders will be 
considered lost to follow-up.  
 
1) The questionnaire will contain the following information and validated scales: 
(a) Demographics* 
(b) Date of colposcopy appointment and date that results were communicated (to measure the 
time interval in days in which results were received by participants) 
(c) Method of colposcopy results communication – family/referring MD versus patient liaison (to 
determine intention to treat versus per protocol) 
(d) State-Trait Anxiety Inventory (STAI) 
(e) Health Anxiety Inventory (HAI) 
(f) Short-Form Patient Satisfaction Questionnaire (PSQ- 18) 
(g) Patient Satisfaction Survey (VSQ-9) 
(h) Self-reported colposcopy result and recommendation (to be compared to actual result on file) 
*Demographic information collected will include: Age, highest level of education, current 
employment, and ethnicity. This information is necessary to understand sample diversity, and 
generalizability of results. 
 

SAFE #H16-03194 v.3 2017-05-29 
6 of 12
Secondary aims in the randomized trial will be to assess the effectiveness and clinical impact of 
the patient liaison intervention by comparing: 1) the interval between generation of colposcopy 
reports and communication of these results to patients; 2) percentage of patients successfully 
contacted and number of contact attempts both by the patient liaison nurse and the research 
coordinator administering the questionnaire; 3) the accuracy of patient’s understanding of their 
colposcopy result, measured by the comparison of self-reported and actual result; and 4) rates of 
patient compliance with recommended follow-up appointments for treatment or repeat 
colposcopy. Patient electronic charts will be reviewed in 6-12 months following the initial 
colposcopy visit to collect data regarding histologic diagnoses, adherence to subsequent follow-
up or treatment appointments and number of missed/cancelled appointments. 
 
PRELIMINARY DATA 
None 
 
PARTICIPANTS 
Recruitment 
Participants will be patients recruited from the Vancouver General Hospital (VGH) Colposcopy 
Clinic who present for their initial colposcopy visit. Initial visits are already marked on the 
current clinic booking system utilized by the clinic healthcare providers. A clinical and research 
nurse who has previously been involved in recruitment of patients for other studies in the clinic 
will approach patients who meet inclusion criteria before or after their appointment as time 
permits and as patients prefer. Patients will be provided with a copy of the consent form that 
contains information about the study and the invitation to participate and will be given an 
opportunity to ask questions. Patients may then decide to participate in the study on the same day 
as their appointment and be consented by the research nurse in the clinic. The nurse will 
explicitly inform them that should they later choose to withdraw their consent, this may be done 
at any time with no impact on the care they receive. The decision of whether to participate will 
not impact any colposcopy visit that follows. All patient information will be stored on a 
password protected computer in an encrypted, password protected file. Following consent, 
patients will be randomized to the patient liaison intervention or control group. Thus, control 
participants will be recruited in the same manner as the intervention group participants. 
 
Inclusion Criteria 
1. Must be 19 years of age or older 
2. Must be patients presenting for an initial visit at the VGH Colposcopy Clinic 
 
Exclusion Criteria 
1. Inability to speak conversational English- required to complete the questionnaire as well as 
provide informed consent to participate  
2. Inability or refusal to provide consent 
3. Pregnant – pregnant women do not usually have biopsies and their subsequent care may be 
much different than non-pregnant patients 
4. Do not have a family physician or referring physician who will provide continuity of care 
following colposcopy – these patients do not have the option of getting results from a family or 
referring physician, so they would bias results.  
 

SAFE #H16-03194 v.3 2017-05-29 
7 of 12
Retention 
Recruitment is anticipated to commence in May or June 2017. With an anticipated 20-30 new 
patients per week in the VGH Colposcopy Clinic and capacity for nurses to approach 50% of 
these (10-15 patients per week), recruitment of 400 patients (with a 50% participation rate of 200 
patients total) will be completed over approximately 9 months and be targeted for completion by 
the end of 2017. Each patient will be followed for approximately 6 months following their initial 
colposcopy visit via chart review at that interval, as it is anticipated that any recommended 
treatments or follow-up visits will take place by 6 months per the clinic standard. Thus, we 
anticipate completion of the trial by July 2018 for a total of 18 months. 
 
Consent 
Consent will be obtained by the colposcopy research nurse at the VGH Colposcopy Clinic who 
will make initial contact with each patient in the waiting room prior to, or following, the 
colposcopy visit. After the patient has been presented with a consent form that includes 
information about the study and an invitation to participate, they will be given the opportunity to 
ask questions regarding participation in the study. Should they be interested in participating, the 
nurse will then review the consent form and the patient will be given the opportunity to sign the 
consent at that time. They will be informed that should they decline to participate or wish to 
withdraw their consent, they may contact the clinic to do so at any time and there will be no 
impact on the care they receive.  
 
Use of Records 
Patient charts from Vancouver General Hospital (VGH) records will be extracted by Marguerite 
Bryce under the supervision of the Principal Investigator (Dr. M. Lee) who is a physician in the 
colposcopy group, and has access to clinical charts on routine basis. In the current standard 
practice at the VGH Colposcopy Clinic, patient electronic and paper charts are shared and 
utilized within the group of colposcopists in the direct provision of care and routine charting, and 
patients frequently will see a different physician for a follow-up appointment than for an initial 
visit. The key information to be drawn from the patient charts includes information regarding 
attended or missed follow-up appointments and adherence to follow-up and treatment 
recommendations-- this is already routinely collected and tracked by the clinic in order to 
optimize clinic efficiency and patient care. Additional information to be extracted from the 
patient chart within 6-12 months of the initial colposcopy visit includes the final pathologic 
result and pathologic diagnoses associated with any treatments, which will be used to compare 
patient self-reported colposcopy results to the actual results as well as assess the impact of 
patient adherence on clinical outcomes. Permission to access and utilize these clinical data will 
be obtained in the initial consent to participate in the study. 
 
Criteria for Early Withdrawal of Participants 
Should any participant request to withdraw from the study prior to being contacted with their 
results by either the patient liaison or their family/referring physician, this will be noted on the 
colposcopy clinic chart and they will default to the clinic standard of care (upon generation of the 
colposcopy report, a note will be sent to the family/referring physician informing them that they 
must follow-up with the patient regarding their colposcopy results).  
 
SAMPLE SIZE CALCULATION 

SAFE #H16-03194 v.3 2017-05-29 
8 of 12
To achieve 90% power for a difference of 5.3 (half of a standard deviation is considered 
clinically significant) in mean anxiety scores (state subscale of the STAI) between the control 
and intervention groups with an assumed pooled standard deviation of 10.6 and alpha of 0.05, the 
required sample size is 85 per group. Accounting for about 15% loss to follow-up, we aim to 
recruit 100 per group with 200 participants in total. With an estimate of 50% participation, the 
research nurse will need to attempt to recruit approximately 400 patients to reach this target. 
 
ANALYSIS 
The mean composite scores will be compared between the intervention and control groups with a 
significance level p<0.05 specifically looking at:  
1) Mean patient anxiety (quantified by the STAI state subscale and HAI scale) related to receipt 
of colposcopy results: The State Trait Anxiety Inventory is an established and widely-used 
anxiety measure with high internal consistency (Cronbach’s  =0.83-0.95 dependent on the 
population studied)10. It contains 20 self-reported items that measure situational or state anxiety, 
and patients rate their agreement with these statements on a four point Likert scale which are 
then aggregated for a composite score. Mean composite trait and state anxiety scores will be 
compared between the two groups using the two-tailed t-test. 
2) Patient satisfaction with the timing and method of communication of their colposcopy results 
and satisfaction with the information they received concerning their diagnosis, procedures, or 
recommended management: these will be quantified by the validated PSQ-18 and VSQ-9 scales 
which have been previously used in patient satisfaction studies at the VGH Colposcopy Clinic. 
Mean scores on the subscales will be compared between the two groups using the two-tailed t-
test. 
3) The accuracy of participant understanding of their colposcopy diagnosis following the 
intervention: for all patients, self-reported colposcopy diagnosis will be compared to the 
diagnosis in the clinic chart and graded as correct or incorrect. A chi-square analysis will be 
performed to assess whether there is a significant difference between the two groups. 
4) Timeliness and rates of communication of patient results: The mean interval in days between 
generation of colposcopy reports and the communication of the result to the patient as well as the 
mean percentage of successfully contacted participants will be compared between the two groups 
using t-tests and z-tests. 
5) Participant adherence to follow-up: patient electronic charts will be reviewed in 6-12 months 
following the colposcopy. The proportion of patients who complete the recommended follow-up 
will be compared between groups using z-test. 
 
BENEFITS 
Those who participate in the patient liaison intervention may benefit from more timely receipt of 
their colposcopy results and recommendations as well as an improved understanding of their 
pathology, the rationale for the recommendations, and support in the logistics of arranging their 
follow-up or treatment visits. The direct contact with the experienced colposcopy nurse who can 
offer support and counseling may also improve the overall patient satisfaction with the 
experience of receiving their results as well as decrease the anxiety or other negative emotions 
associated with the colposcopy process. They may also have the opportunity to access additional 
educational or support resources provided by the colposcopy nurse. Improved adherence to 
colposcopy follow-up and treatment may improve clinical outcomes for patients who participate 
in the intervention. 

SAFE #H16-03194 v.3 2017-05-29 
9 of 12
 
RISKS 
By participating in the Patient Liaison intervention, the intervention group will no longer 
primarily receive their colposcopy results from their family/referring physician and may thus 
experience decreased continuity of care with their referring physician. However, the referring 
physician will still receive a copy of the colposcopy results and recommendations; while they 
will be informed that the colposcopy nurse has already contacted the patient, patients will still be 
able to contact their referring physician or schedule additional follow-up visits at their discretion. 
During the intervention in which the patient liaison contacts the patient with her results, it is 
possible that the patient may have questions or concerns which are beyond the scope of the 
colposcopy nurse. To mitigate this, the colposcopy nurse will be supported by the colposcopists 
who are most responsible provider for each patient who can provide additional information or 
resources as needed. The nurse may then attempt to re-contact the patient at a later time, or 
request permission for the patient to be contacted directly by their colposcopist. In addition, there 
may be questions that are outside the scope of colposcopy care and patients will be asked to 
contact their primary care provider in these cases. Patients may encounter questions that they do 
not feel comfortable answering when completing the questionnaire. Should this occur, patients 
will be instructed that they may leave these unanswered, or at any time withdraw from the study. 
The final page of the questionnaire will include investigator contact information for any 
participant questions or concerns and will also list mental health resources for participants who 
are seeking further support. 
 
CONFIDENTIALITY 
Individual study code numbers will be assigned to each participant that will not be derived from 
any identifying information in order to maintain confidentiality. A linking record that connects 
the participant code number with their patient file will be stored on a password-protected 
encrypted file on a password-protected computer belonging to the study nurse which is located in 
a private locked office. Aside from consent forms which will have the patient’s name, all other 
databases and study information collected will contain only the patient’s study number.  
 
DATA STORAGE 
Study questionnaire data will be collected and managed using REDCap (Research Electronic 
Data Capture), an electronic data capture tool hosted and supported by the Women's Health 
Research Institute (WHRI). REDCap is a secure web-based application designed to support data 
capture for research studies that will identify patients only by their study code. Any 
questionnaires that are completed over the phone with the research coordinator rather than 
directly through the online link by participants will be entered by the coordinator onto REDCap 
using an iPad that is secured and locked in the private office of Dr. Lee or of the study nurse (and 
no data will be stored on the iPad itself). All files with identifying information will be stored on a 
password-protected encrypted file on a password-protected computer in the study nurse’s private 
office. Hard copies of consent forms will be stored in a secured and locked area of the study 
nurse’s private office.  
 
The REDCap data collection application will be used for study data management. Only the 
patient’s study number, and no identifying information, will be used to identify each participant 
within REDCap. REDCap, developed by an NIH- funded consortium of institutional partners, 

SAFE #H16-03194 v.3 2017-05-29 
10 of 12
provides a secure, web-based application for users to enter data and have real time validation 
rules (with automated data type and range checks) at the time of entry. The system offers data 
manipulation with audit trails for reporting, monitoring and querying patient records, and an 
automated export mechanism to statistical applications. REDCap was developed specifically 
around HIPAA security guidelines and has a proven track record with over 400 academic clinical 
research centres hosting the application. The Clinical Research Unit Data Coordinating Centre 
(DCC) will be used as a central location for data processing and management. The DCC will 
house the data in a dedicated, locked server room within the BC Women’s Hospital main site, 
which is secured with 24- hour on-site security guards. Communication over public networks and 
between the web application is encrypted using secure socket layer (SSL) with 256-bit 
encryption or higher. Access between the web application and database is protected by a firewall. 
 
EARLY STOPPAGE 
The entire study could be stopped early should it become evident that the patient liaison is not 
successfully able to contact a significant proportion of the intervention group participants with 
their colposcopy results and recommendations despite multiple attempts (greater than or equal to 
15% by the interim analysis at 50% enrollment). This would be a safety concern given the 
importance of the communication of these results for adherence to treatment and follow-up 
visits, and the plan in this scenario would be to default to the standard of care which would be 
involving the family/referring physician in attempts to contact the patient. In this scenario, the 
investigators would contact all participants to inform them of the reason for the study stoppage, 
providing participants the opportunity to ask any questions or express any concerns at that time. 
Participants in the control arm would be unaffected as they would be proceeding with the current 
standard of care. Referring physicians for participants in the intervention arm would be contacted 
to inform them of the reason for study stoppage and the potential need to contact these 
participants with their colposcopy results and recommendations (return to the standard of care). 
 
CONFLICTS OF INTEREST 
None to declare. 
 
FUNDING 
Funding has been awarded by the Division of Gynaecologic Oncology Research Awards in the 
amount of $13,515. 
 
BUDGET 
Research Assistant (rate $20.74/hour) 
● Focus groups (2 groups of 8-10 patients) = 15 hours: $311 
● Questionnaire administration (n=200 patients x 30 mins/patient = 15 hours): $2,074 
● Documenting follow-up and treatment visit rates and outcomes (n=200 patients x 10-15 
mins/patient = 40 hours): $830 
Research Nurse Recruitment and Patient Liaison (rate $50/hour) 
● Recruitment (400 patients x 50% success for n=200 patients x 15 mins/patient = 100 
hours): $5,000 
● Patient liaison interaction with intervention group (n=100 patients x 30 mins/patient = 50 
hours): $2,500 
Data Management 

SAFE #H16-03194 v.3 2017-05-29 
11 of 12
● iPad for questionnaire and data collection: $1,000 
● SPSS ($400/year): $800 
Knowledge Translation 
● Dissemination of findings (website, social media, conference presentation/poster): $1,000 
 
Total: $13,515

SAFE #H16-03194 v.3 2017-05-29 
12 of 12
BIBLIOGRAPHY 
 
(1) Balasubramani L, Orbell S, Hagger M, Brown V, Tidy J. Can default rates in colposcopy 
really be reduced? BJOG 2008;115:403-408.  
(2) Boone D, Erickson B, Huh W. New insights into cervical cancer screening. JGO 
2012;23:4282-4287.  
(3) Bredart A, Kop J, Efficace F, Beaudeau A, Brito T, Dolbeaut S, Aaronson N, the EORTC 
Quality of Life Group. Quality of care in the outpatient setting from patients’ perspective: a 
systematic review of questionnaires’ content and psychometric performance. Psycho-Oncology 
2015;24:382-394 
(4) Byrom J, Clarke T, Neale J, Dunn P, Hughes G, Redman C, et al. Can pre-colposcopy 
sessions reduce anxiety at the time of colposcopy? J Obstet Gynaecol 2002;22(4):415-420.  
(5) Dietrich A, Tobin J, Cassells A, Robinson C, Greene M, Sox C, et al. Telephone care 
management to improve cancer screening among low-income women. ann intern med 
2006;144:563-571. 
(6) Lerman C, Hanjani P, Caputo C, Miller S, Delmoor E, Nolte S, et al. Telephone counselling 
improves adherence to colposcopy among lower-income minority women. journal of clinical 
oncology 1992;10:330-333.  
(7) Lester H. Is default from colposcopy a problem, and if so what can we do? A systematic 
review of the literature. Br J Gen PRact 1999;49:223-229.  
(8) Litchfield I, Bentham L, Lilford R, McManus R, Greenfield S. Patient perspectives on test 
result communication in primary care: a qualitative study. Br J Gen PRact 2015;65(632):e133-
140.  
(9) Marteau T, Kidd J, Cuddleford L, Walker P. Reducing anxiety in women referred for 
colposcopy using an information booklet. Brit J Health Psych 1996;1(2):181-189.  
(10) McDowell I. Measuring health: a guide to rating scales and questionnaires. 3rd ed. New 
York: Oxford University Press; 2006. 
(11) Nugent L, Tamlyn-Leaman K, Isa N, REardon E, Crumley J. Anxiety and the colposcopy 
experience. Clin Nurs Res 1993;2(3):267-277.  
(12) O'Connor M, Gallagher P, Waller J, Martin C, O'Leary J, Sharp L, et al. Adverse 
psychological outcomes following colposcopy and related procedures: a systemic review. BJOG 
2016;123(1):24-38.  
(13) Perac-Lima S, Ashburner J, Zai A, Chang Y, Oo S, Guimaraes E, et al. Patient navigation 
for comprehensive cancer screening in high risk patients using a population based health 
information technology system. jama internal med 2016;176(7):930-937.  
(14) Towler B, Irwig L, Shelley J. The adequacy of management of women with CIN 2  
and CIN 3 pap smear abnormalities. Med J Aust 1993;159(8):523-528.